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Summary: Results of epidermal growth factor (EOF) receptor in human breast tumours show large variations,
mainly due to the lack of standardization of the assays. Our EOF receptor values are higher than those reported
previously which may be due to the use of the hydroxyapatite to separate bound and non-bound ligand in a
radioligand assay. We found EOF receptors in 58% (103/178) of the tumours (EOF receptor levels: 3 to 625
fmol/mg of membrane protein, χ = 33.3, median = 17.4), with a median Ka of 0.642 nmol/1. There was an inverse
correlation between EGF receptors and estrogen receptors (r = — 0.215, ρ = 0.00002, Kendall correlation). There
was a difference between EGF receptor content in grade II (x = 16.9) and grade III tumours (x = 59.3) (p = 0.027),
but not between histopathological types and lymph node status.
The relevance of EGF receptor largely depends on the reliability of its determination. The standardized EORTC
methodology is a reproducible alternative which will expand EGF receptor determination and permit comparability
of data between laboratories.
Introduction
Epidermal growth factor (EGF) is a 53 amino acid poly- and also serves as specific receptor for transforming
peptide (MT = 6000) isolated from the mouse submaxil- growth factor-α (TGFa) (7).
lary gland (1). The physiological role of EGF, although
not yet completely understood, seems to be to regulate The presence of EGF receptor in human breast tu-
both the proliferation and/or differentiation in vitro and mours has been ^ported by many groups (8). The
in vivo of a wide variety of cell types (2). Particularly, majority of these studies has shown that the presence
it is known to stimulate proliferation of human breast of EGF recePtor is inversely correlated with steroid
cancer cells in culture (3, 4). The biological effects receptor content and provides valuable, although con-
(paracrine or autocrine) of EGF are mediated through troversial, prognostic information in breast cancer (9,
high affinity binding to the specific cell-membrane re- 10)· Ήι«* is sti11 no consensus on EGF receptors role
ceptor (EGF receptor) (2). This receptor is a Μτ ίη prognosis, but recent studies have supported the
= 170000 membrane glycoprotein characterized by ty- hypothesis that EGF receptor may be useful for pre-
rosine kinase activity, and its intracellular domain is ho- dictinS response to endocrine therapy (11) or as a
mologous to sequences of the oncogen c-erbB-2 (5, 6), tarSet for new ^6δ of treatment (12). The most
widely used method of receptor quantitation has been
, radioligand assay in which 125I-labelled EGF is incu-
') Work supported by the FIS grant 90/481 and the Fundacio Au- bated with tumoural membranes. High affinity binding
gust Pi i Sunyer specific for EGF has been reported in 16% to 91%
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of primary breast tumours at levels ranging from 1 to
3600 fmol/mg of protein, with~a median of the distri-
bution ranging from 1.1 to 40 fmol/mg of protein in
the various studies reviewed (8). These large variations
can be explained by the absence of standardization of
tissue-processing and assay conditions (13), and the
heterogeneity of clinical material tested as well.
Our study focuses on the estimation of EOF receptor
using standard methods for iodination of the ligand (14),
separation of bound and free ligand and a binding assay
standardized in accordance with the recommendations
of the EORTC Receptor Study Group (15), and we com-
pared our results with those obtained by other research-
ers with the same methodology. We also studied the as-
sociation between EOF receptor and steroid receptors,
and histopathological characteristics of the tumours.
Materials and Methods
Patients and tumour samples
Surgical samples'were obtained from 178 patients with primary
breast tumours. Thirty-five percent were premenopausal (mean age
= 42.5 years, range = 26—50) and 65% postmenopausal (mean
age = 63.9 years, range = 51-92).
The histopathological tumour type was known in 153 cases. The
post-operative tumour size (pT) was available in 160 cases, the
axillary lymph-node status (pN) in 157 cases, and the Scarff-
Bloom-Richardson histopathological differentiation grade in 132
cases. Patient and tumour characteristics are shown in table 1.
Preparation of tissues
Samples were obtained at surgery, dissected from fat and necrotic
parts and stored at —80 °C until processed. When assayed, the sam-
Tab. 1 Patient and tumour characteristics. Numbers in parenthe-
sis: percentage.
Patients
— pre-menopausal
- post-menopausal
Tumour size
- pTl < 2 cm
- pT2 2- 5 cm
- pT35-10cm
- pT4
Nodal status
— Node-negative
— Node-positive
Tumour histopathology
- intraductal
— ductal
- lobular
— others
Differentiation grade
- G I
- Gi l
- Gill
178
63 (35)
115 (65)
160
51 (32)
76 (47)
6 (4)
27 (17)
157
86 (55)
71 (45)
153
5 (3)
136 (89)
9 (6)
3 (2)
132
15 (11)
56 (42)
61 (47)
pie was homogenized with a Polytron apparatus (3 X 10 s bursts)
in an ice-cold buffer (10 mmol/1 Tris-HCI, 0.5 mmol/1 dithiothrei-
tol, 1.5 mmol/1 EDTA, l mmol/1 monothioglycerol; pH 7.4) (1+5,
w/v). The homogenate was centriftiged for l h at 105000g. The
supernatant was used for the assay of estrogen receptors and pro-
gesterone receptors and the membrane pellet was stored at -80 °C,
up to four weeks, for EGF receptor determination.
Estrogen receptor and progesterone receptor assays
Estrogen receptor (ER) and progesterone receptor (PgR) content
were measured with two enzyme-iminunoassays (ER-EIA and
PgR-EIA Monoclonal kits, Abbott Laboratories). The assays were
performed following the manufacturer's instructions. Tumours with
a steroid receptor content lower than 10 fmol/mg protein were con-
sidered negative in each case.
EGF receptor assay
The stored pellets were resuspended in 2—2.5 ml of assay buffer
(10 mmol/1 K2HPO4/KH2PO4, 1,5 mmol/1 K2EDTA, 3 mmol/1
NaN3,10 mmol/l monothioglycerol, glycerol (volume fraction 0.1),
50 μπιοΐ/ΐ bacitracin; pH 7.4) by means of Polytron homogenizer
(10s burst) on ice. The homogenate was centriftiged 10 min at 800
g to obtain cellular membranes in the supernatant. A 100 μΐ aliquot
was taken for membrane protein determination. To the remaining
cell membrane sample assay buffer containing bovine serum albu-
min was added (final concentration 1 g/1).
EGF receptor was determined by a multiple point ligand binding
assay. Aliquots of cell membrane preparation were incubated with
125I-labelled mouse-EGF tracer (specific activity =1110 Χ 1010
Bq/mmol) at final concentrations ranging from 2.5 to 0.07 iimol/1
for 16 hours at 20 °C. The mouse EGF (Sigma) was iodinated with
the lactoperoxidase — glucose oxidase reagent (Enzymobead, Bio-
Rad). Non-specific binding was assessed by incubation with 250-
fold excess of unlabeled mouse EGF (225 nmol/1). Receptor-bound
and free ligand were separated using hydroxyapatite (DNA grade
Biogel HTP, Βίο-Rad). Hydroxyapatite suspension was added (fi-
nal volume: 240 μΐ), and the assay tubes were incubated for 1
hour at room temperature. Subsequently, tubes were centrifiiged
for 2 min at 800 g and washed twice with phosphate buffer. The
supernatant containing the unbound ligand was decanted and the
hydroxyapatite pellet was assessed in a gamma-ray counter. EGF
receptor values were calculated with Scatchard analysis (16), per-
formed using a nonlinear weighted regression. EGF receptor values
were expressed as fmol/mg of protein. The cut-off point was
3 fmol/mg of membrane protein, which was the lowest concentra-
tion that could be measured reliably (correlation coefficient from
the Scatchard plot higher than 0.7).
Protein analysis
Protein concentration was determined by the method of Lowry et
al. (17). The concentration of the membrane preparation was ad-
justed to the range from 0.5 to 2 g/1.
Statistical analysis
We used non-parametric tests, since the receptor data were not nor-
mally distributed: Mann-Whitney's U test, χ2 analysis for categori-
cal variables, Spearman rank correlation and Kendall rank correla-
tion for continuous variables and multiple regression for multivari-
ate analysis.
Results
EGF receptor
Fifty-eight percent (103/178) of the tumours analyzed
contained specific, saturable, higr* affinity binding sites
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for EOF. Total EOF receptor content ranged from 3 to
625.1 finol/mg of membrane protein, with a mean value
of 22.2 finol/mg (median value of 17.4 fmol/mg).
Scatchard curves showed only one type of association
site, with a median Ka of 0.462 nmol/1. Value distribu-
tion of EOF receptor in the population studied is shown
in figure 1. The histogram shows a log-normal distribu-
tion.
Analysis of the steroid receptor results revealed that
70% (125/178) of the tumour biopsy samples were
estrogen receptor-positive and 50% (89/178) were pro-
gesterone receptor-positive. According to estrogen/pro-
gesterone receptor phenotypes, 49% of tumours were
estrogen/progesterone receptor-positive, 21% were
estrogen receptor-positive/progesterone receptor-nega-
tive, 1% was estrogen receptor-negative/progesterone
receptor-positive and 29% estrogen/progesterone recep-
tor-negative.
EOF receptor was found to be positive in 48% (60/125)
of estrogen receptor-positive and in 81% (43/53) of
estrogen receptor-negative breast tumour biopsy sam-
ples, showing a significant inverse correlation
(χ2 = 16.8, η = 178, ρ = 0.00001), and also in 48%
(43/90) of progesterone receptor-positive and in 68%
(60/80) of progesterone receptor-negative breast tumour
biopsy samples, also with an inverse correlation
(χ2 = 7,6, η = 178, p = 0.006). Table 2 shows the per-
centages of EGF receptor-positive tumours and EOF re-
ceptor content of tumours distributed according to the
combined steroid receptor status.
EGF receptor content in estrogen receptor-positive tu-
mours (x = 18.9, median = 14.8 fmol/mg) was signifi-
cantly lower than that in estrogen receptor-negative tu-
mours (x = 53.4, median = 18.5 fmol/mg, ρ = 0.026).
Tumours with high concentrations of EGF receptor
(> 100 fmol/mg) were all steroid receptor-negative. The
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Fig. 1 Distribution of EGF receptor values in the study popula-
tion. The distribution ranges from 3 to 625.1 fmol/mg membrane
protein (median = 17.4).
content of EGF receptor decreased with increasing ste-
roid receptor values (tab. 3).
We found a negative correlation between EGF receptor
and estrogen receptor content (r = — 0.215,
ρ = 0.00002) and between EGF receptor and progester-
one receptor content (r = -0.128, /? = 0.011; Kendall
rank correlation).
Multivariate analysis with EGF receptor as dependent
variable and steroid receptors as independent variables
showed that only estrogen receptor was independently
associated with EGF receptor (estrogen receptor:
ρ = 0.008, progesterone receptor: ρ = 0.56). This indi-
cates that the association between EGF receptor and pro-
gesterone receptor depends on the strong association be-
tween progesterone receptor and estrogen receptor
(r = 0.4, ρ < 0.000001) (Spearman rank correlation).
In the comparison between pre- and postmenopausal
women we found differences in EGF receptor content
(pre: χ = 55.6 fmol/mg), median = 24.2; post:
χ = 19.34 fmol/mg, median = 13.8; ρ = 0.002). These
results show an inverse relation with the values of estro-
gen receptor, which are higher in the postmenopausal
group. No correlation was observed between EGF recep-
tor status and age.
Histological grade
According to the Scarff-Bloom grading, 53% (8/15) of
grade I tumours, 55% (31/67) of grade II and 64% (397
61) of grade III were EGF receptor-positive. No correla-
tion was observed between EGF receptor and tumour
grade, but considering only the tumours with high EGF
receptor content (> 50 finol/mg), 73% (8/11) were of
grade III, showing a decrease of EGF receptor expres-
sion with tumour differentiation. There was a statistic-
ally significant difference between EGF receptor content
in grade II tumours (x = 16.9 finol/mg), median = 9.7)
and grade III tumours (x = 59.3, median =17.6)
(p = 0.027).
Axillary nodes and histological subtypes
Regardless of the number of axillary lymph nodes in-
vaded, there was no correlation with EGF receptor
content or distribution. There was no difference between
invasive, non-invasive ductal and lobular disease in the
proportion of EGF receptor-positive tumours. No statis-
tical difference was observed in terms of distribution.
Discussion
The percentage of EGF receptor-positivity in human
breast cancer, measured by radioligand binding asssay,
Bur J Clin Chem Clin Biochem 1995; 33 (No 9)
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Tab. 2 Mean EGF receptor content of EOF receptor-positive tumours distributed according to the
combined steroid receptor status. *.
EGF receptor-positive tumours
% n
"/? <0.04; **p < 0.01; *** p < 0.018
EGF receptor content
(rmol/mg)
Estrogen receptor-positive/Progesterone receptor-positive
Estrogen receptor-positive/Progesterone receptor-negative
Estrogen receptor-negative/Progesterone receptor-positive
Estrogen receptor-negative/Progesterone receptor-negative
total
47
50
50
82
58
(41/87)
(19/38)
(1/2)
(42/51)
(103/178)
21.1*,***
\ A Alk AA
r 14.4*,**
17.2
54.2**,***
Tab. 3 Decrease of mean EGF receptor values (fmol/mg of mem-
brane protein) with increase of estrogen receptor and progesterone
receptor content (fmol/mg cytosolic protein) in breast tumours.
Steroid
receptor
(fmol/mg)
< 10
10- 50
50-100
100-250
250-500
>500
Estrogen
receptor
(fmol/mg)
53.4
22.1
25.4
10.9
14.0
5.6
Progesterone
receptor
(frnol/mg)
42.4
24.4
25.0
15.5
13.6
7.1
varied from 16% to 91% (8). The differences in tissue
preparation and assay methodology are the most likely
explanations for these variations. We found EGF recep-
tor to be present in 58% of human breast cancers. Our
positivity rate is very close to that obtained by authors
who used the same methodology (18) and higher than
that of many other authors (8).
Quantitative results of EGF receptor in our study
(x = 33.3 fmol/mg, median = 17.4 fmol/mg) also ex-
ceed most of the values reported by other authors using
radioligand binding assay which may be attributable to
certain aspects of tissue preparation, the use of 800 g
supernatant compared to higher g-values in most re-
ported studies (19-21), and the EORTC methodology
that we followed, such as the use of hydroxypatite to
separate bound and non-bound ligand. Regarding the af-
finity of the receptor for its ligand, we found a Kd sim-
ilar to that described in the literature for breast cancer.
In this sense, we think that discrepancies regarding the
presence of a single or two classes of binding sites may
be due to methodological differences.
There is general agreement that the proportion of EGF
receptpr-positive tumours is significantly higher in
estrogen receptor-negative than in estrogen receptor-
positive tumours. In our study we found 81% of estro-
gen receptor negative tumours to be EGF receptor-posi-
tive. This concurs with in vitro studies of estrogen recep-
tor-negative human breast cancer cell lines, which show
a constitutive expression of EGF receptor (22). The per-
centages of EGF receptor-positivity in each subgroup of
tumours, separated according to the steroid receptor
status, are similar to those obtained previously (13, 18)
by the same EGF receptor method, which is of interest
with regard to the reproducibility of the assay. Further-
more, the use of different methods in the measure of
steroid receptors (dextran-coated charcoal in all previous
works and enzymoimmunoänalysis in our case) does not
seem to influence the results (phenotypical percentages)
obtained for both types of receptors, nor does it alter
the conclusions.
We showed that EGF receptor-positivity and EGF recep-
tor content were inversely associated with steroid recep-
tor content, as reported by many authors (20, 21, 23),
but we found that, performing a multivariate analysis,
the negative association between progesterone receptor
and EGF receptor is not independent and merely shows
the strong association between progesterone receptor
and estrogen receptor.
The inability to detect specific EGF binding in a large
proportion of tumours analyzed (42% of the tumours in
our study), has been attributed to several factors: the
degradation of EGF receptor during homogenization by
the action of endogenous proteases, or occupation of the
receptor by endogenous EGF or EGF-like substances
produced in an autocrine way (24) which impedes the
receptor determination in a binding assay. This is consis-
tent with studies performed on human cell lines for the
production of tumour growth factors (26), but has re-
cently been ruled out by other authors (26). Another pos-
sibility adduced is that since EGF receptor has been
found in normal breast cells, its expression may have
been lost in some tumours as a consequence of processes
of malignant transformation. But this does not seem to
be the case, since in our series we found a significant
relationship (positive) between histopathological grade
and EGF receptor-positive percentage and EGF receptor
content, as reported in other studies (27).
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Some imrnunochemical studies show that in estrogen re-
ceptor-negative/EGF receptor-positive tumours the
estrogen receptor and EOF receptor expressions are mu-
tually exclusive within individual cells (28), and it has
been hypothesized that the expression of estrogen recep-
tor may decrease and EOF receptor may increase in a
particular population of cells in the later stages of malig-
nant progression. In our series this subgroup of tumours
was predominant among those without inverse correla-
tion between estrogen and EOF receptors. We agree that
the estrogen receptor-negative/EGF receptor-positive
subgroup of tumours may be transitional between estro-
gen receptor-positive/EGF receptor-negative and estro-
gen receptor-negative/EGF receptor-positive tumours,
indicating a tendency towards a lack of response to the
therapy.
In our study, the relationship between EOF receptor
and the different histopathological type of tumour was
non-significant. We did not find any relationship be-
tween EGF receptor expression and tumour size, nor
between EGF receptor and the invasion of axillary
lymph nodes, although some authors (8) reported such
relationships.
EGF receptor has been reported as a prognostic marker,
especially in studies for early relapse-free survival, but
the data are rather controversial. In the future, it may be
important as an indicator of response to hormonal ther-
apy and even as a target for therapeutical agents. How-
ever, this relevance is largely dependent on the reliability
of its determination and different methodological ap-
proaches to measuring EGF receptor are not equivalent
in terms of prognostic power. We think that the stan-
dardized methodology for EGF receptor assays, estab-
lished by the EORTC group, is an easy and reproducible
alternative which will expand EGF receptor determina-
tion and permit comparability of EGF receptor data be-
tween laboratories, and offers an important advance for
the clincial trials involving EGF receptor.
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